NEW YORK, Nov. 18 (GenomeWeb News) - Genaissance Pharmaceuticals today announced that it has licensed its HAP genotyping technology platform to consumer product biotech firm Sciona.

In exchange for the technology license, Genaissance obtained a 30 percent equity position in the privately traded UK-based company. Genaissance will receive royalties on any products Sciona develops using the HAP technology.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.